Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ulhas M Nadgir"'
Autor:
Aristides K Maniatis, Samuel J Casella, Ulhas M Nadgir, Paul L Hofman, Paul Saenger, Elena D Chertock, Elena M Aghajanova, Maria Korpal-Szczyrska, Elpis Vlachopapadopoulou, Oleg Malievskiy, Tetyana Chaychenko, Marco Cappa, Wenjie Song, Meng Mao, Per Holse Mygind, Alden R Smith, Steven D Chessler, Allison S Komirenko, Michael Beckert, Aimee D Shu, Paul S Thornton
Publikováno v:
The Journal of clinical endocrinology and metabolism. 107(7)
Purpose The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin in children with growth hormone deficiency. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265b429f9e88e65a20a36daf9f9774cd
https://pubmed.ncbi.nlm.nih.gov/35428884
https://pubmed.ncbi.nlm.nih.gov/35428884
Autor:
Paul Saenger, Samuel J. Casella, Wenjie Song, Allison Komirenko, Aristides K Maniatis, Aimee D Shu, Paul S. Thornton, Paul L. Hofman, Gail J. Mick, Ulhas M Nadgir, Jeremy Warshauer, Elena Chertok, Jessica M Peng, Michael Beckert, Elena Aghajanova
Publikováno v:
Journal of the Endocrine Society
Background Once-weekly TransCon hGH is an investigational long-acting prodrug for growth hormone deficiency (GHD) that consists of 3 components: unmodified growth hormone (hGH; somatropin), an inert carrier that protects it, and a linker that tempora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d074e418ef559e9e4e6a94220629ae9
https://doi.org/10.1210/jendso/bvaa046.2102
https://doi.org/10.1210/jendso/bvaa046.2102
Autor:
Aristides K Maniatis, Gail J. Mick, Aimee D Shu, David B Karpf, Wenjie Song, Mary Jennifer Abuzzahab, Larry Deeb, Larry A. Fox, Paul S. Thornton, Paul Saenger, Jessica M Peng, Katie A. Woods, Kent Reifschneider, Ulhas M Nadgir, Samuel J Casella
Publikováno v:
Journal of the Endocrine Society
Background: The Phase 3 fliGHt Trial evaluated children with growth hormone deficiency (GHD) of a broad range of baseline demographics and treatment durations who switched from daily growth hormone (hGH; somatropin) therapy to once-weekly TransCon hG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18cef01ed6feced761a45558d43332c6
https://doi.org/10.1210/jendso/bvaa046.963
https://doi.org/10.1210/jendso/bvaa046.963
Autor:
Samuel J. Casella, Aimee D Shu, Paul L. Hofman, Ulhas M Nadgir, Paul S. Thornton, Wenjie Song, Allison Komirenko, Michael Beckert, Elena Aghajanova, Steven D Chessler, Aristides K Maniatis, Elena Chertok, Meng Mao, Paul Saenger
Publikováno v:
Journal of the Endocrine Society
Background: Once-weekly TransCon hGH (lonapegsomatropin) is an investigational long-acting prodrug of somatropin in development for GHD. In the pivotal 52-week phase 3 heiGHt trial, lonapegsomatropin demonstrated superior annualized height velocity (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7881b60efa0bf5443b1c81d452948711
http://europepmc.org/articles/PMC8090180
http://europepmc.org/articles/PMC8090180
Publikováno v:
Endocrine Research. 27:41-46
We quantitated serial serum beta-hydroxybutyrate (beta-OHB) levels using the Ketosite method in 9 children with IDDM who were treated for diabetic ketoacidosis (DKA) and compared them to urinary ketone measurements by dipstick. Persistent elevations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10e0c891abf1a9de3bf1a51b8d8ba7c
https://doi.org/10.1081/erc-100107168
https://doi.org/10.1081/erc-100107168